Clovis drug gets BTD tag


The FDA designates Clovis Oncology's (CLVS +1.4%) anti-EGFR drug CO-1686 a Breakthrough Therapy for the treatment of second-line EGFR mutant non-small cell lung cancer in patients with the T790M mutation.

Clovis plans to submit its NDA by mid-2015 based on data from two expansion cohorts of its Phase 1/2 study in EGFR mutant patients with the T790M mutation and from the Tiger2 study which evaluates the drug in T790M-positive patients directly after progression on their first and only TKI therapy.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs